title: Coronary heart disease among Circassians in Israel is not associated with mutations in thrombophilia genes.
abstract: The Muslim Circassian community in Israel represents a unique ethnic community that has never been genetically and medically studied. One hundred and fifty-three randomly selected individuals (91 men and 62 women, ages 35 and older), both healthy or with a history of cardiovascular disease (14 men and 7 women), were studied in a cross-sectional descriptive study for mutations in three genes known to be associated with hypercoagulation. Their medical records were reviewed for risk factors and history of cardiovascular disease (CVD) and thromboembolic events. The mutation FV 1691G --> A in the gene for factor V (FV 1691G --> A), the mutation MTHFR 677C --> T in the gene 5,10-methylenetetrahydrofolate reductase, and the allele G20210A in the gene for prothrombin (PT 20210G --> A) were studied. The mutation FV 1691G --> A was observed in a heterozygous form in 1.3% of 153 studied individuals, while the PT 20210G --> A allele was identified in a heterozygous form in 6.5%. No individual was found homozygous for either of these two mutations. The MTHFR C677T mutation was present in 42.8% of the studied population in a heterozygous form and in 8.6% in a homozygous form. Serum homocysteine, folate, and B12 levels were studied among individuals heterozygous and homozygous for the MTHFR C677T mutation. There was no significant difference in the prevalence of all three mutations between individuals affected with CVD or other forms of thromboembolic disease and healthy individuals. This is the first report of a medical condition and its genetic background among Circassians. The high prevalence of CVD among Circassians was found to be etiologically unrelated to the three mutations studied in the genes for factor V, MTHFR, and prothrombin.
authors.affiliation: Simon Winter Institute for Human Genetics, Bnai Zion Medical Center, and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
authors.forename: Tzipora C
authors.initials: TC
authors.lastname: Falik-Zaccai
authors.forename: Yafa
authors.initials: Y
authors.lastname: Haron
authors.forename: Danny
authors.initials: D
authors.lastname: Eilat
authors.forename: Bakky
authors.initials: B
authors.lastname: Harash
authors.forename: Ekaterina
authors.initials: E
authors.lastname: Golinker
authors.forename: Osamah
authors.initials: O
authors.lastname: Hussein
authors.forename: Rivka
authors.initials: R
authors.lastname: Eisikovits
authors.forename: Zvi
authors.initials: Z
authors.lastname: Borochowitz
authors.forename: Shai
authors.initials: S
authors.lastname: Linn
mesh_terms: D000328:Adult; D000483:Alleles; D003327:Coronary Disease / Q000453:epidemiology / Q000235:genetics*; D003430:Cross-Sectional Studies; D005006:Ethnicity / Q000235:genetics; D005165:Factor V / Q000235:genetics; D005260:Female; D005838:Genotype; D006801:Humans; D007514:Islam; D007557:Israel / Q000453:epidemiology; D016014:Linear Models; D008297:Male; D008754:Methylenetetrahydrofolate Dehydrogenase (NADP) / Q000235:genetics; D008875:Middle Aged; D009154:Mutation; D010641:Phenotype; D011516:Prothrombin / Q000235:genetics; D012307:Risk Factors; D019851:Thrombophilia / Q000235:genetics*
chemical_list: D005165:Factor V; D011516:Prothrombin; D008754:Methylenetetrahydrofolate Dehydrogenase (NADP)